The (EU) authorities & their antibiotic development policy: a changing paradigm

Paul M. Tulkens, MD, PhD

Cellular and Molecular Pharmacology
Louvain Drug Research Institute
Health Science Sector
Université catholique de Louvain
Brussels, Belgium
Disclosures and slides availability

• Research grants
  – Theravance, Astellas, Targanta, Cerexa/Forest, AstraZeneca, Bayer, GSK, Trius, Rib-X, Eumedica
  – Belgian Science Foundation (F.R.S.-FNRS), Ministry of Health (SPF), and Walloon and Brussels Regions

• Speaking fees
  – Bayer, GSK, Sanofi, Johnson & Johnson, OM-Pharma, AstraZeneca

• Decision-making and consultation bodies
  – General Assembly (current) and steering committee (part) of EUCAST
  – European Medicines Agency (external expert)
  – US National Institutes of Health (grant reviewing)

Slides: http://www.facm.ucl.ac.be → Lectures
The end of antibiotic research?

No new antibiotics: is it true?

- A recent article in Genetic Engineering & Biotechnology News identified 66 companies involved in antibiotic research, 86% of which are either small or medium-sized.

- A paper in Journal of Antibiotics (Tokyo) lists 22 new antibiotics launched since 2000 and discusses the development status, mode of action, spectra of activity, historical discovery and origin of the drug pharmacophore (natural product, natural product derived, synthetic or protein/mammalian peptide) of 49 compounds and 6 β-lactamase/β-lactam combinations in active clinical development are discussed.

1. Genetic Engineering and Biotechnology News 14 Aug 2013
   Last accessed: 8 May 2014
New antibiotics: up to phase I – II …

As of February 2014, there are at least 45 new antibiotics with the potential to treat serious bacterial infections in clinical development for the U.S. market.

The success rate for drug development is low (at best, only 1 in 5 candidates that enter human testing will be approved for patients)

The PEW Charitable Trusts (Health Initiatives)
http://www.pewhealth.org/other-resource/antibiotics-currently-in-clinical-development-85899541594
Last accessed: 8 May 2014
New antibiotics: up to phase I – II and III

• There are at least 53 systemic antibiotic NCEs in clinical development, of which 13 have reached Phase III testing.

http://www.biocentury.com/antibioticsncepipeline.htm
Last accessed: 8 May 2014
So what is the real reason?

No Money, guys...
No new antibiotics!

The "Qualy" of antibiotics (*)

- The **quality-adjusted life year** or **quality-adjusted life-year** (QALY) is a measure of **disease burden**, including both the quality and the quantity of life lived. It is used in assessing the **value for money of a medical intervention**.

- If antibiotics **prolong your life of 2 to 10 years**, and the cost of one year of **your life is 20,000 euros**, then the value of the "Qualy" of an antibiotic treatment is **40,000 to 200,000 euros**.

- But the real cost and reimbursement of an antibiotic treatment is **MUCH less**.

- For comparison, the cost of an anticancer treatment for 1 year survival is.... **up to 20,000 to 70,000 euros**… (and the accepted "Qualy" is close to that).

- Find where the problem lies…

---

A too simple example from Belgium?

• For **antibiotics** and **antifungals**, if a medical doctor or a dentist prescribes for an acute treatment:
  – under the name of the active compound: the rules of prescription under INN (*) are of application (delivery of the cheapest preparation available)
  – under a trade name: as from 1\textsuperscript{st} Mai 2012, the pharmacist must deliver the product available in the group of « the cheapest drugs ».

  (last accessed: 7 November 2013)

• The drug acquisition cost for the treatment of a **community acquired pneumonia** following the **recommandations of BAPCOC** (***) (amoxicillin [3 g per day in 3 administrations for 5 to 7 days] is only 13-14 € … (ex-factory price: ~7 €)

  Source: Belgian "Répertoire commenté des médicaments" available at http://www.cbip.be/GGR/Index.cfm?ggrWelk=/nIndex/GGR/Stof/IN_A.cfm
  (last accessed: 7 November 2013)

---

* INN: International International Nonproprietary Name
** BAPCOC: Belgian Antibiotic Policy Coordination Committee
A spiral to death (in Belgium) ?

- For **antibiotics** and **antifungals**, if a medical doctor or a dentist prescribes for an **acute treatment**:
  - under the name of the active compound: the rules of prescription under INN (*) are of application (delivery of the cheapest preparation available)
  - under a trade name: as from **1st Mai 2012**, the pharmacist must deliver the product available in the group of « **the cheapest drugs** ».

  (last accessed: 7 November 2013)

  * INN: International International Nonproprietary Name

- **The drug acquisition cost** for the treatment of a **community acquired pneumonia** following the **recommandations of BAPCOC (**)** (amoxicillin [3 g per day in 3 to 7 days]) is only **13-14 € … (ex-factory price: ~7 €)**

  Belgian "Répertoire commenté des médicaments" available at http://www.cbip.be/GGR/Index.cfm?ggrWelk=/nIndex/GGR/Stof/IN_A.cfm
  (last accessed: 7 November 2013)

  **BAPCOC**: Belgian Antibiotic Policy Coordination Committee

This infernal spiral (to low prices) explains why innovators leave the field
Let us not confuse discovery, development and actual commercialization

Thesis

• There is no real lack of innovation, even if innovation is difficult …

• But there is a real lack of incentive for full clinical development given
  – the time of development that makes the protection period since patent application too short
  – the regulatory hurdles that make development difficult
  – the insistence of authorities to go for low cost that make sales unprofitable

⇒ This is where corrective actions need to be taken …
Trans Atlantic Task Force on Antimicrobial Resistance - TATFAR

2009 EU-US Summit Declaration called for the establishment of “…a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.”
Trans Atlantic Task Force on Antimicrobial Resistance - TATFAR

2009 EU-US Summit Declaration called for the establishment of “…a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.”
Trans Atlantic Task Force on Antimicrobial Resistance - TATFAR

- US and EU membership
- Objective: Promote information exchange, coordination and cooperation between the US and the EU
- 2011 Report: 17 recommended areas for further collaboration

EU-US Summit – November 2009

This slide from van Hengel and D. Dixon, Meet the Experts: Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID, ECCMID 2014, 13 May 2014.
TATFAR Recommendations

• **Issue:** Investigators should consider funding sources and research resources on both sides of the Atlantic to support antimicrobial research and antibacterial product development efforts

• **Recommendation 14:** Publicise funding opportunities to the EU and US research communities
DMID Resources for Researchers

Microbiology and Infectious Diseases Resources
The Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all human infectious agents except HIV.

Funding Opportunities
Apply for grants and contracts to conduct basic research, preclinical development, or clinical evaluation.
- NIH-Wide Funding Opportunity Announcements
- NIAID Funding Opportunity Announcements and Requests for Proposals

Product Development Services and Research Tools and Biological Materials
Request development by DMID-funded contractors of critical information needed to move a product through the product development pathway. Note: Services are contingent upon availability of required preliminary data.

Click on labels below to view information on services.

Web Search Term: DMID Resources
DMID Resources for Researchers

NIH Resources for Researchers offers product development resources, cooperative research and materials licensing agreements, computational biology tools, global research and development projects, and more. Browse the links below for more information.

- **Bioinformatics**
  - Genomics and DNA Analysis
  - Proteomics and Protein Analysis
  - Gene Expression and Transcriptome Analysis
  - Systems Biology
  - View All...

- **Biological Materials**
  - Cell, Tissue and Organism Repositories
  - Model Animals
  - Reagents

- **Translational Research Tools and Services**
  - Biobank Information Services
  - Preclinical Research Resources
  - Clinical Research Resources
  - Vaccines, Diagnostics, and Therapeutics

- **Partnerships and Technology Development**
  - Partnering With NIAD
  - Technology Development

U.S. Department of Health and Human Services • National Institutes of Health

Website Tools
- Print this page
- Get email updates
- Order publications

Research Feature
Microbiome Cloud Helps Researchers Explore Microbial Genetic Data
Read more.

Funding Opportunities

Additional Information From NIH
All microbiology and infectious diseases resources (non-HIV)
Other key changes in the US ...

- **GAIN Act** (Generating Antibiotics Incentives Now) - 2012
  - priority FDA review
  - additional five years of market exclusivity for breakthrough antibiotics that target serious or life-threatening pathogens
  - relaxed its criterion for non-inferiority to within 10%, making it easier to show comparability to drugs already on the market

- **BARDA**: Biomedical Advanced Research and Development Authority
  [within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services]
  - provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.

- **FDA**:
  - new guidance documents (aBSSSI, cUTIs, cIAIs, …) that are considered being significantly better

- **Department of Health and Human Services** (HHS)
  - awarding funds to allow companies to shift funds around an antibiotic programs (portofolio approach; example: GSK antibiotic programme)

- Genetic Engineering and Biotechnology News 14 Aug 2013
  Last accessed: 8 May 2014

- Biomedical Advanced Research and Development Authority
  http://www.phe.gov/about/barda/Pages/default.aspx
  Last accessed: 9 May 2014
Monnies from "Big Bother"

MCM Procurements and Grants

Medical Countermeasures Advanced Research, Development, and Acquisition Contract and Grant Awards

October 21, 2013: New blood test would provide fast results for medical care after anthrax attack.
September 26, 2013: BARDA boosts global ability to respond to pandemics.
September 20, 2013: HHS funds development of freeze-dried platelets for disaster response.
September 19, 2013: BARDA funds development of device to aid burn patients in disasters.
September 19, 2013: HHS replenishes nation’s supply of anthrax vaccine.
August 28, 2013: HHS explores new emergency response use for approved steroid.
September 17, 2013: BARDA funds study of therapy for thermal burns.
September 16, 2013: BARDA evaluates burn dressing for radiation, sulfur mustard burns.
July 30, 2013: BARDA contract supports the development of a more effective skin graft to help burn patients after a radiologic event.
June 25, 2013: BARDA supports new broad-spectrum antibiotic against glanders, melioidosis.
May 24, 2013: BARDA supports new broad-spectrum antibiotics to treat anthrax, tularemia.
May 20, 2013: HHS forms strategic alliance to develop new antibiotics.
April 3, 2013: HHS awards contract to create test to identify resistant influenza viruses.

http://www.phe.gov/newsroom/Pages/mcm-procurements.aspx
Last accessed: 8 May 2014
May 22, 2013: HHS forms strategic alliance to develop new antibiotics

**Date:** May 22, 2013  
**Company:** GlaxoSmithKline US  
**Contract amount:** This agreement is not a contract; other transactional authority was used to create a strategic alliance. BARDA will contribute $40 million over 18 months. The agreement can be extended up to five years and up to a total of $200 million.

**About the contract:** The agreement is the first in which BARDA has taken a portfolio approach with a private sector company instead of contracting to develop a single medical countermeasure. The agreement is flexible, allowing drug candidates to be moved in or out of the portfolio, based on advanced development stage and technical considerations, during joint semi-annual portfolio reviews. Under the agreement, GSK researchers will conduct safety and toxicology testing, clinical pharmacology studies, clinical studies, and non-clinical studies to support approval to treat illnesses caused by bioterrorism agents like anthrax, plague and tularemia, as well as address antibiotic resistance. One of the antibiotics to be further developed under this agreement is GSK944, the first in class of drugs that targets bacterial DNA replication in a unique fashion. GSK has conducted studies in which GSK944 protected or successfully treated animals suffering from anthrax, plague, or tularemia.

**Additional information:** The partnership with GSK is funded by BARDA’s Broad Spectrum Antimicrobials Program. BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through the Broad Agency Announcement BARDA-BAA-12-100-SCL-00011 at www.bao.gov.

**Press Release:** HHS forms strategic alliance to develop new antibiotics

**Anthrax, plague, tularemia … and resistance**
May 24, 2013: BARDA supports new broad-spectrum antibiotic to treat anthrax, tularemia

Date: May 24, 2013
Company: Cempra Pharmaceuticals of Chapel Hill, N.C.
Contract amount: $17.7 million for two years

About the contract: The contract supports studies needed to request FDA approval of a drug called solithromycin to treat adults and children infected with anthrax, tularemia or community-acquired bacterial pneumonia. If approved, the drug would be the first orally administrated antibiotic approved in decades to treat children who develop community-acquired bacterial pneumonia. Studies of the drug’s use in treating anthrax or tularemia will be conducted under the FDA’s Animal Efficacy Rule.

Additional information: BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through a Broad Agency Announcement BARDA-BAA-12-100-SOL-00011 at www.fbo.gov

Press Release: HHS funds drug development for bioterror infections
And even for an aminoglycoside ...

---

**Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin**

April 24, 2013

- Contract to fund Phase 3 superiority study of plazomicin in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections -

South San Francisco, CA, April 24, 2013 – Achaogen, Inc. today announced the award of a $60M contract option from the Biomedical Advanced Research and Development Authority (BARDA). The option supports the conduct of a global Phase 3 superiority study that will evaluate the efficacy and safety of plazomicin in treating patients with serious gram-negative bacterial infections due to CRE. This pathogen-specific clinical study represents a new development approach to address unmet medical needs for multi-drug resistant bacterial infections. The study is expected to start in fourth quarter of 2013.

“We are excited and honored to continue the development of plazomicin in partnership with BARDA,” said Kenneth J. Milan, M.B. Ch.B., Chief Executive Officer and Chief Medical Officer of Achaogen. “The growing prevalence of CRE infections poses a substantial public health threat, given the high mortality rates associated with CRE infections. Plazomicin’s strong potential to address this public health issue and to contribute to global effort to guard against bacterial bioterrorism makes it a critically important agent in the antibacterial pipeline.”

Achaogen Inc

Last accessed: 8 May 2014
Big Brother in Switzerland…

June 25, 2013: BARDA supports new broad-spectrum antibiotic against glanders, melioidosis

Date: June 25, 2013

Company: Basilea Pharmaceutica International Ltd., Basel, Switzerland

Contract amount: BARDA will provide $16.6 million in the first phase of the contract. The contract can be extended up to a total of six years with BARDA contributing up to a total of $89 million.

About the contract: This contract is a cost-sharing public-private partnership. The partnership supports Basilea in conducting studies to evaluate the safety and efficacy of the antibiotic BAL30072 to treat Gram-negative infections including melioidosis, glanders, hospital-acquired pneumonia, and complicated urinary tract infections. Results from these studies will support the eventual filing of a new drug application with the FDA. In addition to showing promise in treating melioidosis and glanders, early studies of BAL30072 have demonstrated the drug’s potential in treating a broad range of multidrug-resistant Gram-negative bacteria commonly found in hospitals.

Additional information: BARDA is seeking additional proposals for broad-spectrum antimicrobials that potentially could treat or prevent diseases caused by bacterial and viral threat agents, and clinically relevant emerging and drug resistant pathogens that through the Broad Agency Announcement BARDA CBER BAA-12-100-SOL-00011 at www.fbo.gov.

Press Release: BARDA supports new broad-spectrum antibiotic
Unless Big Brother comes to your help…

Structure of BAL30072
Numerous attempts have been made to introduce iron-binding functional groups into β-lactams since the 1980s, in order to circumvent the limitations imposed by porin mutation or deletion. BAL30072 is a sulfactam, analogous to tigemonam, with a dihydropyridone iron-chelating group.

http://aac.asm.org/content/54/6/2291.full
AAC June 2010 vol. 54 no. 6 2291-2302
The bacterial challenge: time to react

A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents

ECDC/EMEA Joint Working Group

- assigned on 28 February 2008.
- technical Report accepted by ECDC/EMEA on 23 July 2009
- circulated for information on 20 August 2009.
- published in September 2009

Last accessed: 9 May 2014
What in Europe?

3 Analysis of the research and development pipeline of antibacterial agents

<table>
<thead>
<tr>
<th>Most relevant findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fifteen systemically administered antibacterial agents with a new mechanism of action or directed against a new bacterial target were identified as being under development with a potential to meet the challenge of multidrug resistance. Most of these were in early phases of development and were primarily developed against bacteria for which treatment options are already available.</td>
</tr>
<tr>
<td>There is a particular lack of new agents with new targets or mechanisms of action against multidrug-resistant Gram-negative bacteria. Two such agents with new or possibly new targets and documented activity were identified, both in early phases of development.</td>
</tr>
</tbody>
</table>

The bacterial challenge: time to react

A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents

Last accessed: 9 May 2014
The reaction of the EU...

Communication from the Commission to the European Parliament and the Council

Action plan against the rising threats from Antimicrobial Resistance

Last accessed: 8 May 2014
Communication from the Commission to the European Parliament and the Council

Action plan against the rising threats from Antimicrobial Resistance

5-year Action Plan to fight against AMR based on 12 key actions:

Action n° 6:
*Promote, in a staged approach, unprecedented collaborative research and development efforts to bring new antimicrobials to patients.*

Action n° 7:
*Promote efforts to analyse the need for new antibiotics into veterinary medicine*

The reaction of the EU...

Last accessed: 8 May 2014
The reaction of the EU…

**Action n° 6: To promote, in a staged approach, unprecedented collaborative research and development efforts to bring new antibiotics to patients by:**

- Launching rapidly with EFPIA\(^2\), within the IMI-Joint Undertaking, a programme for research on new antibiotics aimed at improving the efficiency of research and development of new antibiotics through unprecedented open sharing of knowledge.

- Establishing an overarching framework agreement with the industry, defining objectives, commitments, priorities, principles and modes of action for public-private collaboration in a longer term perspective. Mobilising adequate resources, within IMI in particular (and its possible successor), FP7 and in the longer term the forthcoming research and innovation programme 2014-2020 (Horizon 2020), in order to support research and development work, based on criteria and modalities adapted to the specific needs and challenges of antibiotic development. Use the flexibility in the current pharmaceutical legislation to give rapid authorisation to new antibiotics and work with stakeholders and the Member States' authorities towards the establishment of adequate market and pricing conditions for new antibiotics.

- Ensure conditions for and implement fast track procedures for the marketing authorisation of new antimicrobials.
Concerted actions…

HORIZON 2020

AMR RESEARCH AND INNOVATION LANDSCAPE

European Research Council

Marie Skłodowska-Curie actions

Research infrastructures

Societal challenges

- Health, Demographic Change And Wellbeing
- Food, Security, Sustainable Agriculture, Marine and Maritime Research and the Bioeconomy

Innovation in SMEs

Access to risk finance

From van Hengel and D. Dixon, Meet the Experts: Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID, ECCMID 2014, 13 May 2014.
Examples of direct ongoing aids to academic/industrial research (FP7)

Current activities on Diagnostic test development

C4L aims to develop rapid diagnostic tests to link antibiotic prescription with evidence-based diagnosis. Combining the Multiplex Ligation-dependent Probe Amplification (MLPA) and microfluidic technologies will allow determination of viral or bacterial origin, as well as bacterial resistance mechanisms.

PARCIVAL aims to develop an integrated and automated multi-analyte lab-on-a-disk platform for the fast and reliable sample in -> answer out diagnosis of highly infectious respiratory pathogens, resistance patterns and biomarkers for individual severity of the infection.
Examples of direct ongoing aids to academic/industrial research (FP7)

Current activities on Diagnostic test development (INNO-2)

**ROUTINE** aims to develop a test that will integrate sample preparation, DNA amplification and a fluorescent-based readout on one platform to allow direct detection of bacteria causing UTI and the associated antibiotic resistances within 30 min.

**RiD-RTI** aims to develop and evaluate three diagnostics products for the rapid (< 2 hrs) diagnosis of CAP, HAP/VAP and ORTIs. The diagnostics products will be ‘near patient’, reliable, cost-effective and user friendly allowing for detection, identification, and quantification (for selected targets) and molecular drug susceptibility testing of RTIs.

From van Hengel and D. Dixon, Meet the Experts: Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID, ECCMID 2014, 13 May 2014.
Public/Private shares in Europe

Public-private partnerships

- Pooling expertise, knowledge and resources
- Developing incentives to address major unmet medical needs
- Providing a neutral trusted platform to align public and private interests

An opportunity to combine public and private resources for new antimicrobials
IMI in action …

- €2 billion euro budget…
- collaborative research projects and networks of industrial and academic experts…
- collaborative ecosystem for pharmaceutical research and development (R&D)…
- increase Europe's competitiveness globally…
- establish Europe as **the most attractive place for pharmaceutical R&D**
Some IMI ongoing projects in Infectious Diseases...

- **ADVANCE**
  Accelerated development of vaccine benefit-risk collaboration in Europe
  €10,754,061.-

- **BioVacSafe**
  Biomarkers for Enhanced Vaccine Immunosafety
  € 30,200,000.-

- **COMBACTE** *
  Combatting Bacterial Resistance in Europe
  € 250,484,591.-

- **ENABLE** *
  European Gram-negative Antibacterial Engine
  €100,885,487.-

- **RAPP-ID**
  Development of rapid point-of-care test platforms for infectious diseases
  € 14,448,76.-

- **TRANSLOCATION** *
  Molecular basis of the bacterial cell wall permeability
  € 29,328,006.-

Grouped under the ND4BD (New Drugs for Bad Bugs) cupola

≈ 436 x 10⁶ €
out of which about half is paid by the EU
= 215 x 10⁶ €
What are IMI costs comparing to antibiotic expenses in Belgium

**Tableau 3.1.1** Prescriptions des médecins généralistes, spécialistes et dentistes: Répartition entre les groupes anatomiques principaux en 2010

<table>
<thead>
<tr>
<th>Termine ATC</th>
<th>Groupe anatomique principal</th>
<th>Montant brut (milliers EURO)</th>
<th>%</th>
<th>Montant net (milliers EURO)</th>
<th>%</th>
<th>Part personnelle (milliers EURO)</th>
<th>%</th>
<th>DDD/1000 hab/jour</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>J</td>
<td>ANTIINFECTIEUX A USAGE SYSTEMIQUE</td>
<td>318,063</td>
<td>0,9%</td>
<td>263,065</td>
<td>0,7%</td>
<td>54,008</td>
<td>10,4%</td>
<td>31,0</td>
<td>2,7%</td>
</tr>
</tbody>
</table>

Lats accessed: 8 May 2014

~ 436 x 10^6 € out of which about half is paid by the EU = 215 x 10^6 €

which is about what we paid in Belgium for all antibiotics reimbursed in the community

http://www.imi.europa.eu/
Last accessed: 8 May 2014

Grouped under the ND4BD (New Drugs for Bad Bugs) cupola

**ADVANCE**
Accelerated development of vaccine benefit-risk collaboration in Europe
€10,754,061.-

**BioVacSafe**
Biomarkers for Enhanced Vaccine Immunosafety
€30,200,000.-

**COMBACTE** *
Combatting Bacterial Resistance in Europe
€250,484,591.-

**ENABLE** *
European Gram-negative Antibacterial
€100,885,487.-

**RAPP-ID**
Development of rapid point-of-care tests for bacterial infections
€14,448,76.-

**TRANSLOCATION** *
Molecular basis of the bacterial cell wall permeability
€29,328,006.-
How can you COMBACTE?

Combatting Bacterial Resistance in Europe

https://www.combacte.com/
Last accessed: 8 May 2014
How can you COMBACTE?

CLIN-Net Network Participants

As of April 2013, 261 clinical sites in 32 countries have expressed an interest in joining CLIN-Net. In the third quarter of 2013, these sites will be approached with an explorative questionnaire to establish their current experience with clinical trials, their facilities to conduct trials and their need for (additional) GCP training.

Further auditing, site visits and certification will start in 2014.

https://www.combacte.com/?q=node/32
Last accessed: 8 May 2014
How can you COMBACTE?

https://www.combacte.com/
Last accessed: 8 May 2014
Can you ENABLE?

More specifically, the project is working towards:

- identifying **three antibacterial lead molecules** which, following extensive testing, have been identified as having **promising antimicrobial activity**;
- identifying **two antibacterial clinical candidate molecules**. At this stage, the final structure of the molecule is set. The candidate then undergoes more preclinical testing before being studied in humans;
- progressing **at least one compound into** preclinical and phase 1 clinical studies, i.e. early clinical safety testing in humans.

In a nutshell, the unprecedented scientific collaboration carried out within the ENABLE project will **improve early-stage antibacterial drug discovery** and advance the progress of **new medicines** through the scientific pipelines so that they are **ready for testing in patients**.
Will you join ENABLE?

The new antibiotics programmes run by the ENABLE platform will come from European research institutions and small and medium-sized enterprises (SMEs). There are initially seven programmes in the ENABLE portfolio. In addition, a programme arising from an alliance between GSK and Sanofi will also make use of the platform.

This portfolio of programmes will be expanded through open calls for additional antimicrobial programmes from the academic and SME community, to create the most promising portfolio of drug candidates to treat Gram-negative infections. The project has funding to advance a minimum of eight programmes through early testing, with the ultimate goal of obtaining at least one drug molecule for early testing in humans by 2019.

enableprojectfactsheet.pdf
available from http://www.nd4bb-enable.eu/
Last accessed: 8 May 2014
Are you Rapp-ID?

Development of Rapid Point-of-Care Test Platforms for Infectious Diseases

Last accessed: 8 May 2014
Are you Rapp-ID?

RAPP-ID
Development of Rapid Point-Of-Care Test Platforms for Infectious Diseases

<table>
<thead>
<tr>
<th>Participant Name</th>
<th>IMI Funding in €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiff University</td>
<td>75 379</td>
</tr>
<tr>
<td>Interuniversitair Micro-Electronica Centrum vzw</td>
<td>229 726</td>
</tr>
<tr>
<td>Katholieke Universiteit Leuven</td>
<td>366 540</td>
</tr>
<tr>
<td>Kungliga Tekniska Hoegskolan</td>
<td>1 236 972</td>
</tr>
<tr>
<td>LIONEX GmbH</td>
<td>476 900</td>
</tr>
<tr>
<td>Microfluidic ChipShop</td>
<td>467 400</td>
</tr>
<tr>
<td>Mobidiag Oy</td>
<td>306 000</td>
</tr>
<tr>
<td>Q-linea</td>
<td>430 680</td>
</tr>
<tr>
<td>Universite De Geneve</td>
<td>62 100</td>
</tr>
<tr>
<td>Universiteit Antwerpen</td>
<td>1 390 684</td>
</tr>
<tr>
<td>Universiteit Gent</td>
<td>486 900</td>
</tr>
<tr>
<td>University of Cambridge</td>
<td>492 654</td>
</tr>
<tr>
<td>University of Twente</td>
<td>364 003</td>
</tr>
<tr>
<td>Uppsala University</td>
<td>442 500</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>6 828 438</strong></td>
</tr>
</tbody>
</table>


Last accessed: 8 May 2014
IMI Call 11 is on its way…

**TOPICS 6 AND 7: COMBATTING ANTIBIOTIC RESISTANCE:**
NEWDRUGS4BADBUGS (ND4BB)

6. **ND4BB TOPIC 6: EPIDEMIOLOGY RESEARCH AND DEVELOPMENT OF NOVEL SYSTEMIC ANTIBACTERIAL MOLECULES AGAINST HEALTHCARE-ASSOCIATED INFECTIONS DUE TO CLINICALLY CHALLENGING GRAM-NEGATIVE PATHOGENS**

**SUBTOPIC 6A: EPIDEMIOLOGY RESEARCH AND CLINICAL DEVELOPMENT OF A NOVEL BISPECIFIC IGG ANTIBODY, BIS4αPA, FOR THE PREVENTION OF SERIOUS *PSEUDOMONAS AERUGINOSA* DISEASE**

**SUBTOPIC 6B: CLINICAL DEVELOPMENT OF A NOVEL RESISTANCE-BREAKING BETA-LACTAM ANTIBIOTIC, AIC499, IN COMBINATION WITH A BETA-LACTAMASE INHIBITOR (BLI) AGAINST SEVERE BACTERIAL INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS**

Last accessed: 9 May 2014
IMI Call 11 is on its way…

INDICATIVE BUDGET

The indicative EFPIA in-kind contribution is up to EUR 19 000 000
The IMI JU financial contribution will be a maximum of EUR 19 900 000

The total budget is to be divided along the following WPs:

- WP5: Epidemiological study on cUTI
- WP6A: Multiple dose escalation study
- WP6B: Drug-drug interaction study AIC499 with BLI
- WP6C: Mass balance/metabolite identification study
- WP6D: TQT prolongation study
- WP6E: Drug-drug interaction study AIC499/BLI with other drugs
- WP6F: Renal impairment study
- WP6G: Phase 2 PoC trial in cUTI
- WP6H: Phase 2 PoC trial in cIAI
- WP6I: WP6B coordinating centre

Last accessed: 9 May 2014
But what is AIC499?

AIC stands for AiCuris

http://www.aicuris.com/2/Contact.htm
Last accessed: 9 May 2014

https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf
Last accessed: 9 May 2014
But it goes much beyond IMI ...
But it goes much beyond IMI …

The rising awareness of the AMR threat is reflected in a six fold increase in the amount being invested, from some €84 million during the EU’s 1998-2002 research programme to about €522 million for the 2007-13 period.

Most of the EU investment is used to support collaborative projects i.e. international research and innovation teams involving the most capable players from across Europe and abroad.

Last accessed: 8 May 2014
To be transparent to all of you …

<table>
<thead>
<tr>
<th>Project</th>
<th>Description</th>
<th>Coordinator</th>
<th>Email</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOFUN</td>
<td>Novel antifungals to treat resistant organisms</td>
<td>Michael Bromley, University</td>
<td><a href="mailto:mike.bromley@manchester.ac.uk">mike.bromley@manchester.ac.uk</a></td>
<td>€ 4,550,286</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of Manchester</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MON4STRAT</td>
<td>Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-</td>
<td>Bernard Joris, Université de</td>
<td><a href="mailto:bajoris@ulg.ac.be">bajoris@ulg.ac.be</a></td>
<td>€ 5,988,941</td>
</tr>
<tr>
<td></td>
<td>acquired pneumonia, improved dose-dependent efficacy, decreased treatment</td>
<td>Liege</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>duration, and prevention of emergence of resistance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHAGOBURN</td>
<td>Evaluation of phage therapy for the treatment of <em>Escherichia coli</em> and</td>
<td>Patrick Jault, Ministère de</td>
<td><a href="mailto:patrick.jault@sante.defense.gouv.fr">patrick.jault@sante.defense.gouv.fr</a></td>
<td>€ 3,838,422</td>
</tr>
<tr>
<td></td>
<td><em>Pseudomonas aeruginosa</em> burn wound infections (Phase I / II clinical trial)</td>
<td>la Défence</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last accessed: 8 May 2014
To be transparent to all of you …

Why monitoring β-lactams on line?

Paul M. Tulkens, MD, PhD
on behalf of
Louvain Drug Research Institute &
the Louvain Toxicology and Applied Pharmacology
Université catholique de Louvain,
Brussels, Belgium

MON4STRAT kick-off meeting
Liège, Belgium, 31 March 2014

slides available from http://www.facmanucl.ac.be/facman-conferences.htm
Summary / Discussion

• Antibiotics have been a "gold treasure" for Industry for many years until the late 90's

• The decision to "go for generics" made by many countries, the restrictive policies of health authorities, the regulatory hurdles, the rapid attrition of molecules due to emergence of resistance and the short courses of antibiotics have, altogether, discouraged Big Pharma with reorientation towards more profitable businesses even in infectious diseases (think about anti-HIV and, more, recently about the novel anti-Hepatitis C drugs)

• In face of the vaccuum of new commercializations, public authorities have decided (i) to ease the registration process; (ii) to give incentives to companies for discovery; (iii) invest large amounts of money into development programmes.

• This will lead us to a new paradigm that has never been observed so far in which public and private companies cooperate, but where also a large part of the expenses are paid by the tax-payers, supplying what social security does not want to pay (thus, moving from a Bismark to a Beveridge model for health support)
To conclude…

Slides: http://www.facm.ucl.ac.be ➔ Lectures
Back-up
Where does the money come from?

1. Market

Table II. Facts on Small Pharma with Antibiotic Drug Candidates in Phase III

<table>
<thead>
<tr>
<th>Name (Ticker)</th>
<th>Market Cap 02-May-2014</th>
<th>52-week high</th>
<th>02-May-2014 price</th>
<th>Pull Back</th>
<th>2016 revenue estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelion (OTCPK:ALIOF)</td>
<td>11.1 B</td>
<td>106.1</td>
<td>99.41</td>
<td>6%</td>
<td>2.2 B</td>
</tr>
<tr>
<td>Cubist (CBST)</td>
<td>5.4 B</td>
<td>82.12</td>
<td>71.46</td>
<td>13%</td>
<td>1.7 B</td>
</tr>
<tr>
<td>The Medicines Co. (MDCO)</td>
<td>1.69 B</td>
<td>41.28</td>
<td>26.46</td>
<td>36%</td>
<td>950 M</td>
</tr>
<tr>
<td>Durata (DRTX)</td>
<td>359 M</td>
<td>16.99</td>
<td>13.49</td>
<td>21%</td>
<td>100M</td>
</tr>
<tr>
<td>Cempra (CEMP)</td>
<td>304 M</td>
<td>15.39</td>
<td>9.14</td>
<td>39%</td>
<td>50M</td>
</tr>
<tr>
<td>Tetraphase (TTPH)</td>
<td>270 M</td>
<td>17.74</td>
<td>10.50</td>
<td>41%</td>
<td>0</td>
</tr>
<tr>
<td>Achaogen (AKAO)</td>
<td>230 M</td>
<td>19.69</td>
<td>13.76</td>
<td>30%</td>
<td>0</td>
</tr>
</tbody>
</table>

Seeking-α,
Last accessed: 8 May 2014